Literature DB >> 15580313

High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome.

Alexander Schramm1, Volker von Schuetz, Holger Christiansen, Werner Havers, Maria Papoutsi, Jörg Wilting, Lothar Schweigerer.   

Abstract

Amplification of the MYCN oncogene contributes to the malignant progression of human neuroblastomas, but the mechanisms have remained unclear. We have previously demonstrated that N-Myc facilitates angiogenesis by downregulating an angiogenesis inhibitor identified as the inhibin betaA homodimer activin A. Here, we have sought to define the molecular, biological and clinical consequences of activin A expression in human neuroblastoma. We report that enhanced activin A expression suppresses proliferation and colony formation of human neuroblastoma cells with amplified MYCN in vitro; that it inhibits neuroblastoma growth and angiogenesis in vivo; that it is highly expressed in differentiated, but not undifferentiated human neuroblastomas; and that it correlates with favourable outcome of neuroblastoma patients. Our results indicate that high activin A expression plays an important beneficial role in human neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580313     DOI: 10.1038/sj.onc.1208087

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Distinct morphological and immunohistochemical features and different growth rates among four human neuroblastomas heterotransplanted into nude mice.

Authors:  Nobuo Hoshi; Jiro Hitomi; Takashi Kusakabe; Takeaki Fukuda; Masayuki Hirota; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

2.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Authors:  Gaetano Leto; Lorena Incorvaia; Giuseppe Badalamenti; Francesca M Tumminello; Nicola Gebbia; Carla Flandina; Marilena Crescimanno; Giovambattista Rini
Journal:  Clin Exp Metastasis       Date:  2006-07-14       Impact factor: 5.150

3.  Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.

Authors:  Louis Chesler; David D Goldenberg; Isha T Seales; Ronit Satchi-Fainaro; Matt Grimmer; Rodney Collins; Chris Struett; Kim N Nguyen; Grace Kim; Tarik Tihan; Yun Bao; Rolf A Brekken; Gabriele Bergers; Judah Folkman; William A Weiss
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

4.  Female infertility and disrupted angiogenesis are actions of specific follistatin isoforms.

Authors:  Shyr-Yeu Lin; Rebecca G Craythorn; Anne E O'Connor; Martin M Matzuk; Jane E Girling; John R Morrison; David M de Kretser
Journal:  Mol Endocrinol       Date:  2007-10-11

5.  Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.

Authors:  Han Liang; Lydia W T Cheung; Jie Li; Zhenlin Ju; Shuangxing Yu; Katherine Stemke-Hale; Turgut Dogruluk; Yiling Lu; Xiuping Liu; Chao Gu; Wei Guo; Steven E Scherer; Hannah Carter; Shannon N Westin; Mary D Dyer; Roeland G W Verhaak; Fan Zhang; Rachel Karchin; Chang-Gong Liu; Karen H Lu; Russell R Broaddus; Kenneth L Scott; Bryan T Hennessy; Gordon B Mills
Journal:  Genome Res       Date:  2012-10-01       Impact factor: 9.043

6.  Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer.

Authors:  H Kaneda; T Arao; K Matsumoto; M A De Velasco; D Tamura; K Aomatsu; K Kudo; K Sakai; T Nagai; Y Fujita; K Tanaka; K Yanagihara; Y Yamada; I Okamoto; K Nakagawa; K Nishio
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

7.  Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.

Authors:  Melanie Schwermer; Sangkyun Lee; Johannes Köster; Tom van Maerken; Harald Stephan; Angelika Eggert; Katharina Morik; Johannes H Schulte; Alexander Schramm
Journal:  Oncotarget       Date:  2015-06-20

8.  CFC1 is a cancer stemness-regulating factor in neuroblastoma.

Authors:  Koji Chikaraishi; Hisanori Takenobu; Ryuichi P Sugino; Kyosuke Mukae; Jesmin Akter; Masayuki Haruta; Masafumi Kurosumi; Takaho A Endo; Haruhiko Koseki; Naoki Shimojo; Miki Ohira; Takehiko Kamijo
Journal:  Oncotarget       Date:  2017-07-11

9.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

10.  Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.

Authors:  A Schramm; B Schowe; K Fielitz; M Heilmann; M Martin; T Marschall; J Köster; J Vandesompele; J Vermeulen; K de Preter; J Koster; R Versteeg; R Noguera; F Speleman; S Rahmann; A Eggert; K Morik; J H Schulte
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.